Neurocrine Biosciences (NBIX) Aktievy
Neurocrine Biosciences, Inc. upptäcker, utvecklar och kommersialiserar läkemedel för neurologiska, psykiatriska, endokrina och immunologiska sjukdomar i USA och internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 3/6 |
| Framtida tillväxt | 4/6 |
| Tidigare resultat | 5/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
Inga risker upptäckta för NBIX från våra riskkontroller.
NBIX Community Fair Values
Create NarrativeSee what 85 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$244.8
FV
28.9% undervärderad intrinsisk rabatt17.00%
Revenue growth p.a.
1.5k
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
Neurocrine Biosciences, Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$174.10 |
| 52 veckors högsta | US$181.18 |
| 52 veckors lägsta | US$122.14 |
| Beta | 0.39 |
| 1 månads förändring | 8.98% |
| 3 månaders förändring | 33.09% |
| 1 års förändring | 28.84% |
| 3 års förändring | 81.35% |
| 5 års förändring | 85.71% |
| Förändring sedan börsintroduktionen | 1,292.80% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Jul 08
NBIX: Sector Dependence And Product Uptake Uncertainty Will Pressure Forward Returns
Analysts have raised the Neurocrine Biosciences price target by about $8 to $151.68, citing updated models that reflect slightly higher projected revenue growth, profit margins, and a modestly higher future P/E multiple, supported by recent positive research commentary on Ingrezza, Crenessity, Vykat XR, and the broader biotech sector. Analyst Commentary Recent research on Neurocrine Biosciences points to generally constructive sentiment, with several firms lifting price targets and highlighting drivers such as Ingrezza expectations, the addition of Vykat XR, and the runway for key endocrine and neurology assets.Seeking Alpha • Jul 02
Neurocrine Biosciences: Why I Am Upholding A Buy Rating After M&A Deal For Soleno
Summary Neurocrine Biosciences, Inc. remains a Buy, driven by robust growth from Ingrezza, Crenessity, and the recent Vykat acquisition. Q1 2026 revenues rose 44% year-on-year to $811m, with Ingrezza and Crenessity annualizing at blockbuster levels and Vykat showing rapid ramp-up. NBIX stock valuation reflects high-growth expectations; forward P/S ~5.1x and P/E ~30x, justified by an expanding commercial portfolio and pipeline catalysts. Patent protection through 2038 for Ingrezza and solid balance sheet support long-term growth, with pipeline approvals offering further upside potential. Read the full article on Seeking AlphaRecent updates
Uppdatering av berättelse • Jul 08
NBIX: Sector Dependence And Product Uptake Uncertainty Will Pressure Forward Returns
Analysts have raised the Neurocrine Biosciences price target by about $8 to $151.68, citing updated models that reflect slightly higher projected revenue growth, profit margins, and a modestly higher future P/E multiple, supported by recent positive research commentary on Ingrezza, Crenessity, Vykat XR, and the broader biotech sector. Analyst Commentary Recent research on Neurocrine Biosciences points to generally constructive sentiment, with several firms lifting price targets and highlighting drivers such as Ingrezza expectations, the addition of Vykat XR, and the runway for key endocrine and neurology assets.Seeking Alpha • Jul 02
Neurocrine Biosciences: Why I Am Upholding A Buy Rating After M&A Deal For Soleno
Summary Neurocrine Biosciences, Inc. remains a Buy, driven by robust growth from Ingrezza, Crenessity, and the recent Vykat acquisition. Q1 2026 revenues rose 44% year-on-year to $811m, with Ingrezza and Crenessity annualizing at blockbuster levels and Vykat showing rapid ramp-up. NBIX stock valuation reflects high-growth expectations; forward P/S ~5.1x and P/E ~30x, justified by an expanding commercial portfolio and pipeline catalysts. Patent protection through 2038 for Ingrezza and solid balance sheet support long-term growth, with pipeline approvals offering further upside potential. Read the full article on Seeking Alpha
Uppdatering av berättelse • Jun 24
NBIX: Future Upside Will Rely On Expanding Rare Disease Franchise
Analysts have nudged their price target for Neurocrine Biosciences higher to $243.06 from $241.76, citing updated views on revenue growth, profit margins, and future P/E expectations following recent coverage initiations and the addition of Soleno Therapeutics' Vykat XR to the portfolio. Analyst Commentary Recent Street research on Neurocrine Biosciences highlights a generally constructive tone, with several firms updating views on the stock following the completion of the Soleno Therapeutics acquisition and fresh coverage initiations.Analysartikel • Jun 19
Neurocrine Biosciences (NBIX) Stock Could Be 18% Undervalued After ENDO 2026 CRENESSITY Data
Neurocrine Biosciences (NBIX) is in focus after new CRENESSITY data at ENDO 2026 highlighted hormone normalization in classic CAH due to 11ß hydroxylase deficiency, alongside two-year cardiometabolic and bone health outcomes in adults. See our latest analysis for Neurocrine Biosciences. At a share price of $158.29, Neurocrine Biosciences has given investors a 23.97% 90 day share price return and a 25.08% 1 year total shareholder return, pointing to momentum that has built alongside ENDO 2026...
Uppdatering av berättelse • Jun 09
NBIX: Future Upside Will Depend On Rare Disease Portfolio Execution
Analysts have lifted the fair value estimate for Neurocrine Biosciences by about $6 to $192.88, reflecting updated views on revenue growth, profitability and valuation after the Soleno acquisition, along with recent Street research highlighting a long runway for key drugs and additional contributions from Vykat XR. Analyst Commentary Recent Street research around Neurocrine Biosciences has been broadly constructive, with several firms updating models after the Soleno acquisition and new readthroughs on key products.Uppdatering av berättelse • May 26
NBIX: Pipeline Execution And Integration Risks Will Shape Balanced Future Returns
Analysts lifted their fair value target for Neurocrine Biosciences by about $3 to $144, citing updated assumptions for revenue growth of 14.83%, a profit margin of 18.43%, and a recalibrated future P/E of 21.28x that reflects confidence in the long runway of its key approved drugs and potential contributions from Crenessity and osavampator. Analyst Commentary Recent Street research on Neurocrine Biosciences highlights a mix of optimism around the company’s approved therapies and emerging pipeline, alongside selective caution on execution and valuation.Analysartikel • May 08
Neurocrine Biosciences, Inc. Just Recorded A 61% EPS Beat: Here's What Analysts Are Forecasting Next
Neurocrine Biosciences, Inc. ( NASDAQ:NBIX ) investors will be delighted, with the company turning in some strong...Uppdatering av berättelse • May 07
NBIX: Future Upside Will Depend On Execution Across Two Core Franchises
The updated analyst price target for Neurocrine Biosciences moves to $241.76 from $203.91, with analysts pointing to higher modeled revenue growth and slightly richer future P/E assumptions, partly balanced by a modestly lower profit margin outlook and a small change in the discount rate. Analyst Commentary Recent Street research on Neurocrine Biosciences shows a cluster of price target changes and fresh coverage that tilt bullish overall, even with a few modest trims.Uppdatering av berättelse • Apr 21
NBIX: Future Upside Will Hinge On Tardive Dyskinesia Franchise Execution
The updated analyst price target for Neurocrine Biosciences increases to $186.45 from $178.04. Analysts attribute the change to more supportive long-term earnings expectations and higher assumed future P/E multiples, even as they refine revenue growth and margin assumptions.Uppdatering av berättelse • Apr 07
NBIX: Mixed 2026 Guidance And Policy Risks Will Shape Future Returns
Analysts have made a small upward adjustment to the fair value estimate for Neurocrine Biosciences to about $140.54, reflecting updated price targets that weigh mixed revisions across the Street against generally constructive views on Ingrezza and Crenessity. Analyst Commentary Street research around Neurocrine Biosciences has been active, with a mix of supportive views on key assets like Ingrezza and Crenessity and a series of price target tweaks that pull in different directions.Uppdatering av berättelse • Mar 24
NBIX: Future Upside Will Depend On Crenessity Adoption And Pipeline Progress
Analysts have trimmed the blended price target for Neurocrine Biosciences slightly to about $178, reflecting modest tweaks to growth, discount rate and P/E assumptions, while incorporating mixed but generally constructive views on Ingrezza and Crenessity uptake from recent research updates. Analyst Commentary Street research on Neurocrine Biosciences has been active, with several firms adjusting price targets and models around recent earnings, updated guidance and new information on Ingrezza and Crenessity.Uppdatering av berättelse • Mar 09
NBIX: 2026 Guidance Execution And CAH Competition Will Shape Future Returns
Analysts have kept the fair value estimate for Neurocrine Biosciences steady at $140, while revising their models slightly to reflect updated revenue growth, margins, and P/E assumptions following recent earnings, guidance, and a mix of modest price target cuts and a fresh $160 Outperform initiation. Analyst Commentary Across recent research, you are seeing a mix of optimism around the pipeline and commercial assets along with a cluster of more cautious valuation resets.Uppdatering av berättelse • Feb 23
NBIX: Execution On 2026 Guidance And Competitive CAH Data Will Shape Outlook
Neurocrine Biosciences' updated analyst price target of $140.00, down from $169.00, reflects refreshed models after Q4 results and 2026 guidance, with analysts still pointing to Ingrezza and Crenessity as key drivers in their long term assumptions despite recent target trims across the Street. Analyst Commentary Street research around Neurocrine Biosciences has turned more mixed, with several bearish analysts trimming price targets following Q4 results and updated 2026 guidance, while a few others have made only modest upward adjustments.Uppdatering av berättelse • Feb 09
NBIX: Future Returns Will Hinge On Crenessity Execution And Pipeline Delivery
Analysts made a modest trim to their Neurocrine Biosciences price targets, generally landing around the high US$170s. Updated models reflect slightly more conservative revenue growth assumptions and a marginally higher discount rate, partly offset by steady margin expectations and supportive views on Crenessity and Ingrezza.Uppdatering av berättelse • Jan 24
NBIX: Future Revenue Will Depend On Execution Across Two Key Franchises
Analysts have raised their fair value estimate for Neurocrine Biosciences to about US$204 from US$192. This reflects updated assumptions that include slightly stronger revenue growth, higher profit margins and a lower future P/E multiple after recent Street research refined expectations for Ingrezza, Crenessity and competitor dynamics.Uppdatering av berättelse • Jan 10
NBIX: Commercial Execution And Pipeline Progress Will Drive Future Shareholder Returns
Analysts have raised their fair value estimate for Neurocrine Biosciences from about $177.92 to $179.66, reflecting updated models that incorporate recent price target revisions, current product performance, and expectations regarding future competition and commercial execution. Analyst Commentary Recent research updates show a mix of optimism and caution around Neurocrine Biosciences, with most price target moves clustering around the high $160s to mid $180s and reflecting updated models on current products, competitive developments in congenital adrenal hyperplasia, and spending to support commercial execution.Uppdatering av berättelse • Dec 17
NBIX: Advancing CNS Pipeline Readouts Will Drive Future Shareholder Returns
Analysts have modestly increased their average price target for Neurocrine Biosciences by about $3, to roughly $178, citing stronger than expected product performance, sustained Ingrezza growth momentum, and growing confidence in the company’s advancing pipeline despite potential IRA related pricing headwinds. Analyst Commentary Street research remains broadly constructive on Neurocrine, with multiple firms nudging price targets higher as they factor in stronger execution, commercial visibility for Ingrezza and Crenessity, and a maturing late stage pipeline.Uppdatering av berättelse • Dec 03
NBIX: Late-Stage CNS Pipeline Readouts Will Drive Future Shareholder Value
Analysts have nudged their blended price target for Neurocrine Biosciences modestly higher to the high $170s to low $180s range, reflecting stronger than expected Ingrezza and Crenessity performance, confidence in commercial execution ahead of IRA related headwinds, and growing optimism around the longer term pipeline. Analyst Commentary Bullish analysts largely frame the recent pullback as a mismatch between robust fundamentals and short term market sentiment, with multiple firms lifting price targets into the mid $160s to mid $190s range even as shares consolidated.Uppdatering av berättelse • Nov 19
NBIX: Late-Stage Pipeline Advancements Will Drive Shareholder Value Amid Industry Headwinds
Neurocrine Biosciences' analyst price target has increased modestly, up by $3 to $174. Analysts cite ongoing strong commercial performance, expanded sales force initiatives, and a robust late-stage pipeline as supporting factors for sustained growth potential.Uppdatering av berättelse • Nov 05
NBIX: Expanding Commercial Momentum And Pipeline Advances Will Drive Shareholder Value
The analyst price target for Neurocrine Biosciences has been raised from approximately $170 to $175 per share. This reflects analyst optimism about the company’s strong recent earnings, expanded sales efforts, and ongoing commercial and pipeline momentum.Uppdatering av berättelse • Oct 22
Analysts Boost Neurocrine Biosciences Price Target Citing Strong Revenue Outlook and Clinical Results
Analysts have raised their price target for Neurocrine Biosciences from $168.25 to $169.95. They cite stronger revenue outlooks for key products and supportive recent clinical trial data as the main reasons for this adjustment.Aktieägarnas avkastning
| NBIX | US Biotechs | US Marknad | |
|---|---|---|---|
| 7D | 0% | -3.1% | -0.9% |
| 1Y | 28.8% | 32.8% | 19.4% |
Avkastning vs industri: NBIX presterade sämre än US Biotechs branschen som gav 32.8 % under det senaste året.
Avkastning vs Marknaden: NBIX översteg US marknaden som gav 19.4 % under det senaste året.
Prisvolatilitet
| NBIX volatility | |
|---|---|
| NBIX Average Weekly Movement | 4.9% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stabil aktiekurs: NBIX har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: NBIX s veckovolatilitet ( 5% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1992 | 2,000 | Kyle Gano | www.neurocrine.com |
Neurocrine Biosciences, Inc. upptäcker, utvecklar och marknadsför läkemedel för neurologiska, psykiatriska, endokrina och immunologiska sjukdomar i USA och internationellt. Bolagets produkter omfattar INGREZZA för behandling av tardiv dyskinesi och korea i samband med Huntingtons sjukdom, Orilissa tabletter för behandling av endometrios, Oriahnn kapslar för behandling av myom i livmodern och CRENESSITY för behandling av kongenital binjurehyperplasi, samt erbjuder produkter under namnen ALKINDI och Efmody. Bolagets produktkandidater i klinisk utveckling inkluderar NBI-1076986 för behandling av rörelsestörningar; Osavampator för otillräckligt behandlingssvar vid egentlig depression; NBI-1117568 för behandling av schizofreni och bipolär mani; NBI-1117567 för behandling av Alzheimers sjukdom; NBI 921355 för behandling av epilepsi; NBIP-01435 för behandling av medfödd binjurebarkshyperplasi; NBIP-2118 för behandling av fetma och relaterade metabola sjukdomar; och NBI-1070770 för behandling av egentlig depression; och NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675 och NBI-1065890 för neuropsykiatriska och neurologiska tillstånd.
Neurocrine Biosciences, Inc. Sammanfattning av grunderna
| NBIX grundläggande statistik | |
|---|---|
| Börsvärde | US$17.81b |
| Vinst(TTM) | US$668.60m |
| Intäkter(TTM) | US$3.10b |
26.2x
P/E-förhållande5.6x
P/S-förhållandeÄr NBIX övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| NBIX resultaträkning (TTM) | |
|---|---|
| Intäkter | US$3.10b |
| Kostnad för intäkter | US$1.11b |
| Bruttovinst | US$2.00b |
| Övriga kostnader | US$1.33b |
| Intäkter | US$668.60m |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
Jul 30, 2026
| Vinst per aktie (EPS) | 6.65 |
| Bruttomarginal | 64.37% |
| Nettovinstmarginal | 21.55% |
| Skuld/egenkapitalförhållande | 0% |
Hur har NBIX utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/07/13 05:03 |
| Aktiekurs vid dagens slut | 2026/07/13 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Neurocrine Biosciences, Inc. bevakas av 39 analytiker. 22 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Martha Freitag | Argus Research Company |
| Brian Skorney | Baird |
| Aydin Huseynov | Benchmark Company |